Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 1.00 |
| ▸ | F3 | P13726 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 9/20 | 0.77 |
| ▸ | F2 | P00734 | 7/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5146604 | 0.96 | F7 (0.92) | F7F3F10F2PRSS1 | |
| SCHEMBL5054216 | 0.87 | F7 (1.00) | F7F3F10F2PRSS1 | |
| SCHEMBL5054219 | 0.87 | F7 (1.00) | F7F3F10F2PRSS1 | |
| SCHEMBL6788956 | 0.86 | F7 (1.00) | F7F3F10F2PRSS1 | |
| SCHEMBL6786371 | 0.86 | F7 (1.00) | F7F3F10F2PRSS1 | |
| SCHEMBL6789076 | 0.86 | F7 (1.00) | F7F3F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL6027119 | 0.83 | F7 (0.92) | F7F3F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL5048828 | 0.83 | F7 (0.92) | F7F3F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL6027515 | 0.82 | F7 (0.92) | F7F3F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL5048831 | 0.82 | F7 (0.92) | F7F3F10F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | F7, SERPINE1, HABP2 | F7 1/4885F3 62/4885F10 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.